Defense contractor Leidos (NYSE:LDOS) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 3.7% year on year to $4.4 billion. The company expects the full year’s revenue to be around $18.2 billion, close to analysts’ estimates. Its non-GAAP profit of $3.13 per share was 7.6% above analysts’ consensus estimates.
Is now the time to buy LDOS? Find out in our full research report (it’s free for active Edge members).
Leidos (LDOS) Q1 CY2026 Highlights:
- Revenue: $4.4 billion vs analyst estimates of $4.28 billion (3.7% year-on-year growth, 2.8% beat)
- Adjusted EPS: $3.13 vs analyst estimates of $2.91 (7.6% beat)
- Adjusted EBITDA: $614 million vs analyst estimates of $581.7 million (14% margin, 5.6% beat)
- The company lifted its revenue guidance for the full year to $18.2 billion at the midpoint from $17.7 billion, a 2.8% increase
- Management slightly raised its full-year Adjusted EPS guidance to $12.30 at the midpoint
- Operating Margin: 11.5%, in line with the same quarter last year
- Backlog: $48.37 billion at quarter end, up 4.5% year on year
- Market Capitalization: $17.26 billion
StockStory’s Take
Leidos reported first quarter results that exceeded Wall Street’s expectations, but the market responded negatively, reflecting concerns beyond the headline numbers. Management attributed the quarter’s performance to robust growth in intelligence and digital infrastructure segments and cited strong demand for advanced defense products such as the AGM-190A missile and unmanned surface vehicles. CEO Thomas Bell emphasized that Leidos’ ability to scale new AI-driven solutions across its five growth pillars—including managed health and energy resilience—was central to the quarter’s revenue gains. However, management also noted that profitability in the Defense segment was tempered by early-stage development programs and ongoing fixed price contract pressures.
Looking forward, Leidos’ raised full-year outlook is underpinned by recent acquisitions and a healthy backlog, but management highlighted the potential for uneven results in the near term. CFO Chris Cage cautioned that second quarter revenue and margins may dip as investments ramp up, though he expects a stronger second half as new contracts and integration of the Entrust and Kudu businesses contribute more meaningfully. Management is focused on accelerating production of defense technologies and further embedding AI into customer solutions, with Bell stating, “AI is not a threat to our business model, it’s an accelerant.” The company remains optimistic about long-term growth across its defense, digital, and health portfolios, even as it navigates near-term operational headwinds.
Key Insights from Management’s Remarks
Management credited broad-based demand across defense technology, intelligence, and health with driving Q1 results, while recent acquisitions and portfolio realignment set the stage for future growth.
-
Defense tech momentum: Leidos saw strong demand for its advanced defense products, particularly the AGM-190A small cruise missile, which is moving to accelerated production following successful tests. Management noted growing procurement interest in unmanned surface vehicles (MUSVs) and counter-drone technologies, highlighting the operational deployment of the Seahawk MUSV as a key milestone.
-
AI integration as a differentiator: The company is leveraging artificial intelligence to streamline both internal processes and customer solutions. Bell explained that AI “makes us faster and more efficient,” allowing Leidos to focus on solving complex mission-critical problems, especially within highly secure government environments. This approach is seen as amplifying—not disrupting—the company’s competitive advantages.
-
Health segment expansion: Leidos secured a $456 million Military OneSource award, allowing it to shift military care from reactive to proactive, and launched the My Service Treatment Record pilot with the Department of War and Veterans Administration. These initiatives embed Leidos’ digital platforms into customer workflows, supporting both growth and retention in managed health services.
-
Acquisition-driven growth: The recent acquisitions of Entrust and Kudu have accelerated Leidos’ entry into energy infrastructure services and offensive cyber capabilities. The Entrust integration is ahead of schedule, and the combined energy business has already expanded its pipeline to $10 billion, with early customer wins in battery storage and energy generation plant design.
-
Portfolio realignment and capital discipline: Leidos is streamlining its focus toward its five strategic growth pillars and forming a joint venture for its SES business. Management highlighted disciplined capital deployment, including a multiyear $100 million venture investment, and noted that elevated capital expenditures are temporary and aligned with near-term production scale-up needs.
Drivers of Future Performance
Management’s outlook for the rest of the year emphasizes growth from new contract wins, acquisitions, and ongoing AI adoption, but acknowledges near-term margin and revenue variability tied to investment timing.
-
Backlog and contract pipeline: With a $48.37 billion backlog and growing proposal activity, management expects new awards—especially in Defense Tech and energy infrastructure—to drive revenue acceleration in the second half. Bell highlighted a $9 billion Defense Tech pipeline and a $10 billion post-Entrust energy pipeline as key contributors.
-
Investment in growth pillars: Increased capital expenditures are planned to support scaling in defense production and digital health programs. CFO Chris Cage noted that near-term investments may dampen Q2 profitability, but are expected to deliver higher margins as new programs, like ALPS and IFPC, ramp up and achieve scale.
-
Integration risk and market headwinds: Ongoing integration of Entrust and Kudu, as well as portfolio realignment, present execution risks. Additionally, management cited continued government procurement delays and fixed price contract pressures as potential sources of short-term margin volatility, though these are expected to ease by year-end.
Catalysts in Upcoming Quarters
In the next few quarters, the StockStory team will watch (1) the pace at which new defense and energy infrastructure contracts convert to revenue, (2) margin stabilization as recent investments and acquisitions are integrated, and (3) continued progress in scaling AI-enabled solutions across managed health and digital segments. The ability to execute on portfolio realignment and monitor capital discipline will also be important markers of success.
Leidos currently trades at $138.22, down from $148.81 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.